

Active substances set

Search phrase: selpercatinib

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Colon and rectum cancer

Selpercatinib	Selpercatinib as monotherapy is indicated for the treatment of adults and paediatric patients 2 years of age and older with: – advanced RET fusion-positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted. For biomarker-based patient selection.	NO REIMBURSEMENT ESMO

Tracheal, bronchus, and lung cancer

Selpercatinib	Selpercatinib as monotherapy is indicated for the treatment of adults with: - advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor; - advanced RET fusion-positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted.	REIMBURSEMENT WITH RESTRICTIONS ESMO